Nuveen’s Agile Therapeutics AGRX Stock Holding History

Nuveen’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-119	Closed	-$493K	–	3591
2021 Q1	$493K	Sell	119 -5	-4%	-$27K	﹤0.01%	3102
2020 Q4	$713K	Sell	124 -36	-23%	-$212K	﹤0.01%	2921
2020 Q3	$974K	Hold	160	–	–	﹤0.01%	2710
2020 Q2	$888K	Buy	+160	New	+$831K	﹤0.01%	2666

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's AGRX Position: Q2 2021 in Review

Nuveen sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 119 shares — an estimated $493K sold.

Nuveen first reported a position in AGRX in Q2 2020 and held it in 4 quarters. The position peaked at $974K in Q3 2020. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

Nuveen reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
Nuveen sold 119 Agile Therapeutics shares in Q2 2021, an estimated $493K.
Nuveen first reported a position in Agile Therapeutics in Q2 2020 and held it in 4 quarters.
Nuveen's Agile Therapeutics position peaked at $974K in Q3 2020.
64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.